Last $22.16 USD
Change Today +0.24 / 1.09%
Volume 497.8K
RPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:12 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

repros therapeutics inc (RPRX) Snapshot

Open
$22.01
Previous Close
$21.92
Day High
$22.55
Day Low
$21.80
52 Week High
09/24/13 - $29.79
52 Week Low
08/1/14 - $12.61
Market Cap
512.1M
Average Volume 10 Days
1.3M
EPS TTM
$-1.32
Shares Outstanding
23.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REPROS THERAPEUTICS INC (RPRX)

repros therapeutics inc (RPRX) Related Bloomberg News

View More Bloomberg News

repros therapeutics inc (RPRX) Related Businessweek News

No Related Businessweek News Found

repros therapeutics inc (RPRX) Details

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase II clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

28 Employees
Last Reported Date: 08/11/14
Founded in 1987

repros therapeutics inc (RPRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $521.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $275.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $191.3K
Chief Medical Officer
Total Annual Compensation: $181.1K
Vice President of Research & Development
Total Annual Compensation: $183.3K
Compensation as of Fiscal Year 2013.

repros therapeutics inc (RPRX) Key Developments

Repros Therapeutics Inc. - Special Call

Repros Therapeutics Inc. - Special Call

Repros Therapeutics Inc. Reports Top Line Results for the First of Two Identical Pivotal Studies

Repros Therapeutics Inc. reported top line results for the first of two identical pivotal studies comparing Androxal(R) to FDA approved topical gel (Androgel(R) 1.62) and placebo. In this study, ZA-305, Androxal(R) exhibited superiority in several assessments, particularly the two co-primary endpoints: percent change from baseline in average sperm concentration and percent of subjects considered to be responders. A responder is defined as an individual achieving a 24 hour average testosterone in the normal range with associated average sperm concentration >= 10 million/mL. Multiple secondary endpoints also showed statistically significant differences between the Androxal(R) and T gel groups. These include: change in the important pituitary signaling hormones LH and FSH; percent of subjects that become severely oligospermic (< 10 million sperm/mL); induction of hormone dependence via assessment of morning testosterone levels comparing baseline to one week after the end of dosing; and impact on testicular size at the end of the dosing period. ZA-305 was designed to enroll 120 men, 40 each into three parallel arms: Androxal(R), approved topical gel and placebo. All three arms were blinded and ‘double dummied,’ meaning men received both an active dose and a placebo mimicking the other active. Men on placebo received two placebos, one for each active. The study was of 17 week duration, 16 weeks dosing and 1 week follow-up. Men (<= 60 years of age) enrolled in the study exhibited sperm counts in the normal range at baseline (> 15 million/mL) on two separate days separated by at least two days. Men also exhibited morning testosterones of < 300 ng/dL on both of those days to be eligible to enter the study. Results for Study ZA-305: The number of subjects enrolled into the study was 127, of which 117 completed. Of the enrolled subjects, 44, 42 and 41 subjects were randomized to Androxal(R), a Topical T, and Placebo, respectively. The mean age of the subjects was 47, 45 and 48 years for the Androxal(R), Topical T, and Placebo subjects, respectively. Baseline BMI was similar for the three groups, 33.8, 33.1 and 33.5 for the Androxal(R), Topical T, and Placebo subjects, respectively. The first primary efficacy endpoint was the percent change from baseline in sperm concentration. The percent change from baseline was found to be unchanged from baseline for Androxal(R) -treated subjects and those treated with Topical T experienced a median 33% decrease from their baseline concentration. This difference was found to be statistically different from baseline (p = 0.0007) as well as statistically different from the Androxal(R) results (p = 0.0004). Table 1 provides additional information on sperm concentration.

Repros Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Repros Therapeutics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenues and other income increased to $2,000 for the three month period ended June 30, 2014 as compared to $1,000 for the same period in the prior year. Net loss was $8.7 million or $0.38 per basic and diluted share as compared to a net loss of $7.2 million or $0.38 per basic and diluted share for the same period in 2013. Total revenues and other income was $5,000 for the six month period ended June 30, 2014 as compared to $2,000 for the same period in the prior year. The increases for the three and six month periods ended June 30, 2014 as compared to the same periods in the prior year were primarily due to an increase in interest income as a result of increased cash balances. Net cash of approximately $14.8 million and $12.8 million was used in operating activities during the six month periods ended June 30, 2014 and 2013, respectively. The major use of cash for operating activities for the six month period ended June 30, 2014 was to fund clinical development programs and associated administrative costs. The net loss for the six month period ended June 30, 2014, was $17.3 million or $0.75 per basic and diluted share as compared to a net loss of $14.6 million or $0.79 per basic and diluted share for the same period in 2013. The increases in net loss for both the three and six month periods ended June 30, 2014 as compared to the same period in 2013 were primarily due to an increase in expenses related to the clinical development of Androxal, an increase in costs of professional services and increased payroll and benefits expenses due to increased headcount.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPRX:US $22.16 USD +0.24

RPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPRX.
View Industry Companies
 

Industry Analysis

RPRX

Industry Average

Valuation RPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPROS THERAPEUTICS INC, please visit www.reprosrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.